Becker's Hospital Review has reported the following drug company layoffs since Oct. 19. They are listed below, beginning with the most recent.
1. 2.3k Eli Lilly employees accept buyouts
More than 2,300 employees at Eli Lilly's U.S. operations accepted voluntary buyouts as part of the drugmaker's plan to eliminate 3,500 positions worldwide by Dec. 31.
2. Amgen to lay off 200 research & development workers
Amgen, a biopharmaceutical company headquartered in Thousand Oaks, Calif., will lay off 200 research and development workers by the end of the year.
- Genentech to lay off 13% of workforce at California plant
Genentech, a biologics drugmaker owned by Roche, will slash 130 jobs or about 13 percent of its workforce at its Vacaville, Calif., plant as the company faces increased biosimilar competition.
- Merck to lay off 1.8k sales reps: 4 things to know
Merck will eliminate three U.S. sales teams that promote drugs for primary care, disease-focused endocrinology and hospital chronic care.
- Novartis will close US generics plant, eliminating 450 positions
Novartis will eliminate 450 U.S. jobs over the next two years during the gradual closure of its generic drug manufacturing plant in Broomfield, Colo.
More articles on supply chain:
6 medical groups to Congress: We need a 'comprehensive strategy' for critical drug shortages
AHA urges FDA to address saline bag shortage
Merck earns FDA approval for antiviral drug: 3 things to know